← Back

SUSMED,Inc.

SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.

Price · split & dividend adjusted
News & notes moving 4263.JP
4263.JP

ABEJA to Establish Singapore Subsidiary; Globing Plans Profit Increase and Higher Dividend

In individual announcements released on the 26th, ABEJA resolved to establish a wholly-owned subsidiary in Singapore. Globing plans a significant profit increase and higher dividend for the fiscal year ending May 2027 (IFRS). Susmed's exclusive sales contract with Shionogi for its insomnia disorder app has ended. Nexera received a milestone payment of approximately 1.591 billion yen related to its partner Neurocrine's Phase 2 trial for cognitive impairment in Alzheimer's disease. Kasumigaseki Capital sold a property held for sale (Miami development land) for its first U.S. project, and Yamaha announced the partial sale of its shares in Yamaha Motor. Matsui Securities set its interim dividend for the fiscal year ending March 2027 at 28 yen (compared to 25 yen in the same period last year), and Medical Net resolved the material weakness in internal control over financial reporting that had been disclosed.
ウエルスアドバイザー·10hRead more ▾